AST(SGOT 0 8 0 8 B-clinical_variable
) 8 9 8 9 I-clinical_variable
, 9 10 9 10 O
ALT(SGPT 11 19 11 19 B-clinical_variable
) 19 20 19 20 I-clinical_variable
, 20 21 20 21 O
and 22 25 22 25 O
alkaline 26 34 26 34 B-clinical_variable
phosphatase 35 46 35 46 I-clinical_variable
≤ 47 48 47 48 O
3 49 50 49 50 B-upper_bound
times 51 56 51 56 I-upper_bound
the 57 60 57 60 I-upper_bound
upper 61 66 61 66 I-upper_bound
limit 67 72 67 72 I-upper_bound
of 73 75 73 75 I-upper_bound
normal 76 82 76 82 I-upper_bound

Absolute 0 8 83 91 B-clinical_variable
neutrophil 9 19 92 102 I-clinical_variable
count 20 25 103 108 I-clinical_variable
( 26 27 109 110 I-clinical_variable
ANC 27 30 110 113 I-clinical_variable
) 30 31 113 114 I-clinical_variable
≥ 32 33 115 116 O
1000 34 38 117 121 B-lower_bound
/ 38 39 121 122 I-lower_bound
mm3 39 42 122 125 I-lower_bound

Active 0 6 126 132 O
systemic 7 15 133 141 B-chronic_disease
infection 16 25 142 151 I-chronic_disease
requiring 26 35 152 161 O
therapy 36 43 162 169 B-treatment
, 43 44 169 170 O
positive 45 53 171 179 O
tests 54 59 180 185 O
for 60 63 186 189 O
Hepatitis 64 73 190 199 B-chronic_disease
B 74 75 200 201 I-chronic_disease
surface 76 83 202 209 O
antigen 84 91 210 217 O
or 92 94 218 220 O
Hepatitis 95 104 221 230 B-chronic_disease
C 105 106 231 232 I-chronic_disease
ribonucleic 107 118 233 244 O
acid 119 123 245 249 O
( 124 125 250 251 O
RNA 125 128 251 254 O
) 128 129 254 255 O

Administration 0 14 256 270 O
of 15 17 271 273 O
chemotherapy 18 30 274 286 B-treatment
or 31 33 287 289 O
any 34 37 290 293 O
other 38 43 294 299 O
cancer 44 50 300 306 B-treatment
therapy 51 58 307 314 I-treatment
in 59 61 315 317 O
the 62 65 318 321 O
pre 66 69 322 325 O
- 69 70 325 326 O
operative 70 79 326 335 O
period 80 86 336 342 O

As 0 2 343 345 O
there 3 8 346 351 O
is 9 11 352 354 O
potential 12 21 355 364 O
for 22 25 365 368 O
hepatic 26 33 369 376 O
toxicity 34 42 377 385 O
with 43 47 386 390 O
nivolumab 48 57 391 400 B-treatment
or 58 60 401 403 O
nivolumab 61 70 404 413 O
/ 70 71 413 414 O
ipilimumab 71 81 414 424 B-treatment
combinations 82 94 425 437 I-treatment
, 94 95 437 438 O
drugs 96 101 439 444 O
with 102 106 445 449 O
a 107 108 450 451 O
predisposition 109 123 452 466 O
to 124 126 467 469 O
hepatoxicity 127 139 470 482 O
should 140 146 483 489 O
be 147 149 490 492 O
used 150 154 493 497 O
with 155 159 498 502 O
caution 160 167 503 510 O
in 168 170 511 513 O
patients 171 179 514 522 O
treated 180 187 523 530 O
with 188 192 531 535 O
nivolumab 193 202 536 545 B-treatment
- 202 203 545 546 I-treatment
containing 203 213 546 556 I-treatment
regimen 214 221 557 564 I-treatment

Creatinine 0 10 565 575 B-clinical_variable
≤ 11 12 576 577 O
1.5 13 16 578 581 B-upper_bound
x 17 18 582 583 I-upper_bound
ULN 19 22 584 587 I-upper_bound
or 23 25 588 590 O
creatinine 26 36 591 601 B-clinical_variable
clearance 37 46 602 611 I-clinical_variable
( 47 48 612 613 I-clinical_variable
CrCl 48 52 613 617 I-clinical_variable
) 52 53 617 618 I-clinical_variable
≥40 54 57 619 622 O
mL 58 60 623 625 I-lower_bound
/ 60 61 625 626 I-lower_bound
min 61 64 626 629 I-lower_bound

Diagnostic 0 10 630 640 O
core 11 15 641 645 B-treatment
biopsy 16 22 646 652 I-treatment
specimens 23 32 653 662 O
must 33 37 663 667 O
be 38 40 668 670 O
reviewed 41 49 671 679 O
by 50 52 680 682 O
a 53 54 683 684 O
faculty 55 62 685 692 O
pathologist 63 74 693 704 O
at 75 77 705 707 O
SKCCC 78 83 708 713 O
or 84 86 714 716 O
MSKCC 87 92 717 722 O

ECOG 0 4 723 727 B-clinical_variable
performance 5 16 728 739 I-clinical_variable
status 17 23 740 746 I-clinical_variable
0 24 25 747 748 B-lower_bound
- 25 26 748 749 O
1 26 27 749 750 B-upper_bound

Either 0 6 751 757 O
a 7 8 758 759 O
formalin 9 17 760 768 B-treatment
fixed 18 23 769 774 I-treatment
paraffin 24 32 775 783 I-treatment
block 33 38 784 789 I-treatment
or 39 41 790 792 O
a 42 43 793 794 O
minimum 44 51 795 802 O
of 52 54 803 805 O
fifteen 55 62 806 813 B-lower_bound
5 63 64 814 815 O
- 64 65 815 816 O
micron 65 71 816 822 O
tissue 72 78 823 829 O
sections 79 87 830 838 O
( 88 89 839 840 O
slides 89 95 840 846 O
) 95 96 846 847 O
of 97 99 848 850 O
tumor 100 105 851 856 B-treatment
biopsy 106 112 857 863 I-treatment
sample 113 119 864 870 O
must 120 124 871 875 O
be 125 127 876 878 O
available 128 137 879 888 O
for 138 141 889 892 O
biomarker 142 151 893 902 O
evaluation 152 162 903 913 O
( 163 164 914 915 O
study 164 169 915 920 O
pathologist 170 181 921 932 O
must 182 186 933 937 O
review 187 193 938 944 O
for 194 197 945 948 O
adequacy 198 206 949 957 O
of 207 209 958 960 O
sampling 210 218 961 969 O
) 218 219 969 970 O

Female 0 6 971 977 B-gender
CrCl 7 11 978 982 B-clinical_variable
= 12 13 983 984 O
( 14 15 985 986 O
140 15 18 986 989 O
- 19 20 990 991 O
age 21 24 992 995 B-age
in 25 27 996 998 O
years 28 33 999 1004 O
) 33 34 1004 1005 O
x 35 36 1006 1007 O
weight 37 43 1008 1014 O
in 44 46 1015 1017 O
kg 47 49 1018 1020 O
x 50 51 1021 1022 O
0.85 52 56 1023 1027 O
72 57 59 1028 1030 O
x 60 61 1031 1032 O
serum 62 67 1033 1038 B-clinical_variable
creatinine 68 78 1039 1049 I-clinical_variable
in 79 81 1050 1052 O
mg 82 84 1053 1055 O
/ 84 85 1055 1056 O
dL 85 87 1056 1058 O

For 0 3 1059 1062 O
this 4 8 1063 1067 O
reason 9 15 1068 1074 O
, 15 16 1074 1075 O
women 17 22 1076 1081 B-gender
of 23 25 1082 1084 O
child 26 31 1085 1090 O
- 31 32 1090 1091 O
bearing 32 39 1091 1098 O
potential 40 49 1099 1108 O
( 50 51 1109 1110 O
WOCBP 51 56 1110 1115 O
) 56 57 1115 1116 O
and 58 61 1117 1120 O
men 62 65 1121 1124 O
must 66 70 1125 1129 O
agree 71 76 1130 1135 B-contraception_consent
to 77 79 1136 1138 I-contraception_consent
use 80 83 1139 1142 I-contraception_consent
adequate 84 92 1143 1151 I-contraception_consent
contraception 93 106 1152 1165 I-contraception_consent
( 107 108 1166 1167 O
hormonal 108 116 1167 1175 B-contraception_consent
or 117 119 1176 1178 I-contraception_consent
barrier 120 127 1179 1186 I-contraception_consent
method 128 134 1187 1193 I-contraception_consent
of 135 137 1194 1196 I-contraception_consent
birth 138 143 1197 1202 I-contraception_consent
control 144 151 1203 1210 I-contraception_consent
; 151 152 1210 1211 O
abstinence 153 163 1212 1222 B-contraception_consent
) 163 164 1222 1223 O
prior 165 170 1224 1229 O
to 171 173 1230 1232 O
study 174 179 1233 1238 O
entry 180 185 1239 1244 O
and 186 189 1245 1248 O
for 190 193 1249 1252 O
the 194 197 1253 1256 O
duration 198 206 1257 1265 O
of 207 209 1266 1268 O
study 210 215 1269 1274 O
participation 216 229 1275 1288 O
and 230 233 1289 1292 O
for 234 237 1293 1296 O
up 238 240 1297 1299 O
to 241 243 1300 1302 O
23 244 246 1303 1305 B-upper_bound
weeks 247 252 1306 1311 I-upper_bound
after 253 258 1312 1317 O
the 259 262 1318 1321 O
last 263 267 1322 1326 O
dose 268 272 1327 1331 O
of 273 275 1332 1334 O
nivolumab 276 285 1335 1344 B-treatment

Hemoglobin 0 10 1345 1355 B-clinical_variable
≥ 11 12 1356 1357 O
9 13 14 1358 1359 B-lower_bound
g 15 16 1360 1361 I-lower_bound
/ 16 17 1361 1362 I-lower_bound
dL 17 19 1362 1364 I-lower_bound

High 0 4 1365 1369 O
risk 5 9 1370 1374 O
NSCLC 10 15 1375 1380 B-cancer
with 16 20 1381 1385 O
resection 21 30 1386 1395 O
option 31 37 1396 1402 O
for 38 41 1403 1406 O
potential 42 51 1407 1416 O
cure 52 56 1417 1421 O
, 56 57 1421 1422 O
as 58 60 1423 1425 O
assessed 61 69 1426 1434 O
by 70 72 1435 1437 O
a 73 74 1438 1439 O
faculty 75 82 1440 1447 O
surgeon 83 90 1448 1455 O
at 91 93 1456 1458 O
SKCCC 94 99 1459 1464 O
or 100 102 1465 1467 O
MSKCC 103 108 1468 1473 O

Histologically 0 14 1474 1488 O
proven 15 21 1489 1495 O
non 22 25 1496 1499 B-cancer
- 25 26 1499 1500 I-cancer
small 26 31 1500 1505 I-cancer
- 31 32 1505 1506 I-cancer
cell 32 36 1506 1510 I-cancer
lung 37 41 1511 1515 I-cancer
cancer 42 48 1516 1522 I-cancer
( 49 50 1523 1524 O
core 50 54 1524 1528 B-treatment
biopsy 55 61 1529 1535 I-treatment
required 62 70 1536 1544 O
) 70 71 1544 1545 O

History 0 7 1546 1553 O
of 8 10 1554 1556 O
allergy 11 18 1557 1564 O
to 19 21 1565 1567 O
study 22 27 1568 1573 B-allergy_name
drug 28 32 1574 1578 I-allergy_name
components 33 43 1579 1589 I-allergy_name

Inhaled 0 7 1590 1597 B-treatment
or 8 10 1598 1600 I-treatment
topical 11 18 1601 1608 I-treatment
steroids 19 27 1609 1617 I-treatment
and 28 31 1618 1621 O
adrenal 32 39 1622 1629 B-treatment
replacement 40 51 1630 1641 I-treatment
doses 52 57 1642 1647 I-treatment
> 58 59 1648 1649 O
10 60 62 1650 1652 B-lower_bound
mg 63 65 1653 1655 I-lower_bound
daily 66 71 1656 1661 O
prednisone 72 82 1662 1672 B-treatment
equivalents 83 94 1673 1684 O
are 95 98 1685 1688 O
permitted 99 108 1689 1698 O
in 109 111 1699 1701 O
the 112 115 1702 1705 O
absence 116 123 1706 1713 O
of 124 126 1714 1716 O
active 127 133 1717 1723 O
autoimmune 134 144 1724 1734 B-chronic_disease
disease 145 152 1735 1742 I-chronic_disease

Known 0 5 1743 1748 O
positive 6 14 1749 1757 O
history 15 22 1758 1765 O
or 23 25 1766 1768 O
positive 26 34 1769 1777 O
test 35 39 1778 1782 O
for 40 43 1783 1786 O
Human 44 49 1787 1792 B-chronic_disease
Immunodeficiency 50 66 1793 1809 I-chronic_disease
Virus 67 72 1810 1815 I-chronic_disease
or 73 75 1816 1818 O
Acquired 76 84 1819 1827 B-chronic_disease
ImmunoDeficiency 85 101 1828 1844 I-chronic_disease
Syndrome 102 110 1845 1853 I-chronic_disease
( 111 112 1854 1855 I-chronic_disease
AIDS 112 116 1855 1859 I-chronic_disease
) 116 117 1859 1860 I-chronic_disease

Leukocytes 0 10 1861 1871 B-clinical_variable
≥ 11 12 1872 1873 O
2,000 13 18 1874 1879 B-lower_bound
/ 18 19 1879 1880 I-lower_bound
mm3 19 22 1880 1883 I-lower_bound

Male 0 4 1884 1888 B-gender
CrCl 5 9 1889 1893 B-clinical_variable
= 10 11 1894 1895 O
( 12 13 1896 1897 O
140 13 16 1897 1900 O
- 17 18 1901 1902 O
age 19 22 1903 1906 B-age
in 23 25 1907 1909 O
years 26 31 1910 1915 O
) 31 32 1915 1916 O
x 33 34 1917 1918 O
weight 35 41 1919 1925 B-clinical_variable
in 42 44 1926 1928 I-clinical_variable
kg 45 47 1929 1931 I-clinical_variable
x 48 49 1932 1933 O
1.00 50 54 1934 1938 O
72 55 57 1939 1941 O
x 58 59 1942 1943 O
serum 60 65 1944 1949 B-clinical_variable
creatinine 66 76 1950 1960 I-clinical_variable
in 77 79 1961 1963 I-clinical_variable
mg 80 82 1964 1966 I-clinical_variable
/ 82 83 1966 1967 I-clinical_variable
dL 83 85 1967 1969 I-clinical_variable

Men 0 3 1970 1973 B-gender
with 4 8 1974 1978 O
female 9 15 1979 1985 B-gender
partners 16 24 1986 1994 O
( 25 26 1995 1996 O
WOCBP 26 31 1996 2001 O
) 31 32 2001 2002 O
that 33 37 2003 2007 O
are 38 41 2008 2011 O
not 42 45 2012 2015 B-contraception_consent
willing 46 53 2016 2023 I-contraception_consent
to 54 56 2024 2026 I-contraception_consent
use 57 60 2027 2030 I-contraception_consent
contraception 61 74 2031 2044 I-contraception_consent

Platelet 0 8 2045 2053 B-clinical_variable
count 9 14 2054 2059 I-clinical_variable
≥ 15 16 2060 2061 O
100,000 17 24 2062 2069 B-lower_bound
/ 24 25 2069 2070 I-lower_bound
mm3 25 28 2070 2073 I-lower_bound

Prior 0 5 2074 2079 B-treatment
therapy 6 13 2080 2087 I-treatment
with 14 18 2088 2092 I-treatment
an 19 21 2093 2095 I-treatment
anti 22 26 2096 2100 I-treatment
- 26 27 2100 2101 I-treatment
PD-1 27 31 2101 2105 I-treatment
, 31 32 2105 2106 O
anti 33 37 2107 2111 B-treatment
- 37 38 2111 2112 I-treatment
PD 38 40 2112 2114 I-treatment
- 40 41 2114 2115 I-treatment
L1 41 43 2115 2117 I-treatment
, 43 44 2117 2118 O
anti 45 49 2119 2123 B-treatment
- 49 50 2123 2124 I-treatment
PDL-2 50 55 2124 2129 I-treatment
, 55 56 2129 2130 O
or 57 59 2131 2133 O
anti 60 64 2134 2138 B-treatment
- 64 65 2138 2139 I-treatment
CTLA-4 65 71 2139 2145 I-treatment
antibody 72 80 2146 2154 I-treatment
( 81 82 2155 2156 O
or 82 84 2156 2158 O
any 85 88 2159 2162 O
other 89 94 2163 2168 O
antibody 95 103 2169 2177 O
targeting 104 113 2178 2187 O
T 114 115 2188 2189 O
cell 116 120 2190 2194 O
co 121 123 2195 2197 O
- 123 124 2197 2198 O
regulatory 124 134 2198 2208 O
pathways 135 143 2209 2217 O
) 143 144 2217 2218 O

Prisoners 0 9 2219 2228 O
or 10 12 2229 2231 O
subjects 13 21 2232 2240 O
who 22 25 2241 2244 O
are 26 29 2245 2248 O
involuntarily 30 43 2249 2262 O
incarcerated 44 56 2263 2275 O
or 57 59 2276 2278 O
compulsorily 60 72 2279 2291 O
detained 73 81 2292 2300 O
for 82 85 2301 2304 O
treatment 86 95 2305 2314 B-treatment
of 96 98 2315 2317 O
either 99 105 2318 2324 O
a 106 107 2325 2326 O
psychiatric 108 119 2327 2338 B-chronic_disease
or 120 122 2339 2341 O
physical 123 131 2342 2350 B-chronic_disease
( 132 133 2351 2352 O
e.g. 133 137 2352 2356 O
infectious 138 148 2357 2367 B-chronic_disease
disease 149 156 2368 2375 I-chronic_disease
) 156 157 2375 2376 O
illness 158 165 2377 2384 O

Sexually 0 8 2385 2393 O
active 9 15 2394 2400 O
fertile 16 23 2401 2408 O
men 24 27 2409 2412 B-gender
must 28 32 2413 2417 O
use 33 36 2418 2421 B-contraception_consent
effective 37 46 2422 2431 I-contraception_consent
barrier 47 54 2432 2439 I-contraception_consent
birth 55 60 2440 2445 I-contraception_consent
control 61 68 2446 2453 I-contraception_consent
if 69 71 2454 2456 O
their 72 77 2457 2462 O
partners 78 86 2463 2471 O
are 87 90 2472 2475 O
WOCBP 91 96 2476 2481 O
for 97 100 2482 2485 O
up 101 103 2486 2488 O
to 104 106 2489 2491 O
31 107 109 2492 2494 B-upper_bound
weeks 110 115 2495 2500 I-upper_bound
after 116 121 2501 2506 I-upper_bound
the 122 125 2507 2510 O
last 126 130 2511 2515 O
dose 131 135 2516 2520 O
of 136 138 2521 2523 O
nivolumab 139 148 2524 2533 B-treatment

Should 0 6 2534 2540 O
a 7 8 2541 2542 O
woman 9 14 2543 2548 B-gender
become 15 21 2549 2555 O
pregnant 22 30 2556 2564 B-pregnancy
or 31 33 2565 2567 O
suspect 34 41 2568 2575 O
she 42 45 2576 2579 O
is 46 48 2580 2582 O
pregnant 49 57 2583 2591 O
while 58 63 2592 2597 O
she 64 67 2598 2601 O
or 68 70 2602 2604 O
her 71 74 2605 2608 O
partner 75 82 2609 2616 O
is 83 85 2617 2619 O
participating 86 99 2620 2633 O
in 100 102 2634 2636 O
this 103 107 2637 2641 O
study 108 113 2642 2647 O
, 113 114 2647 2648 O
she 115 118 2649 2652 O
should 119 125 2653 2659 O
inform 126 132 2660 2666 O
her 133 136 2667 2670 O
treating 137 145 2671 2679 O
physician 146 155 2680 2689 O
immediately 156 167 2690 2701 O

Squamous 0 8 2702 2710 B-cancer
or 9 11 2711 2713 I-cancer
non 12 15 2714 2717 I-cancer
- 15 16 2717 2718 I-cancer
squamous 16 24 2718 2726 I-cancer
histology 25 34 2727 2736 O

Subjects 0 8 2737 2745 O
are 9 12 2746 2749 O
excluded 13 21 2750 2758 O
if 22 24 2759 2761 O
they 25 29 2762 2766 O
have 30 34 2767 2771 O
an 35 37 2772 2774 O
active 38 44 2775 2781 O
, 44 45 2781 2782 O
known 46 51 2783 2788 O
or 52 54 2789 2791 O
suspected 55 64 2792 2801 O
autoimmune 65 75 2802 2812 B-chronic_disease
disease 76 83 2813 2820 I-chronic_disease

Subjects 0 8 2821 2829 O
are 9 12 2830 2833 O
permitted 13 22 2834 2843 O
to 23 25 2844 2846 O
enroll 26 32 2847 2853 O
if 33 35 2854 2856 O
they 36 40 2857 2861 O
have 41 45 2862 2866 O
vitiligo 46 54 2867 2875 B-chronic_disease
, 54 55 2875 2876 O
type 56 60 2877 2881 B-chronic_disease
I 61 62 2882 2883 I-chronic_disease
diabetes 63 71 2884 2892 I-chronic_disease
mellitus 72 80 2893 2901 I-chronic_disease
, 80 81 2901 2902 O
residual 82 90 2903 2911 O
hypothyroidism 91 105 2912 2926 B-chronic_disease
due 106 109 2927 2930 O
to 110 112 2931 2933 O
autoimmune 113 123 2934 2944 B-chronic_disease
condition 124 133 2945 2954 I-chronic_disease
only 134 138 2955 2959 O
requiring 139 148 2960 2969 O
hormone 149 156 2970 2977 B-treatment
replacement 157 168 2978 2989 I-treatment
, 168 169 2989 2990 O
psoriasis 170 179 2991 3000 B-chronic_disease
not 180 183 3001 3004 O
requiring 184 193 3005 3014 O
systemic 194 202 3015 3023 B-treatment
treatment 203 212 3024 3033 I-treatment
, 212 213 3033 3034 O
or 214 216 3035 3037 O
conditions 217 227 3038 3048 O
not 228 231 3049 3052 O
expected 232 240 3053 3061 O
to 241 243 3062 3064 O
recur 244 249 3065 3070 O
in 250 252 3071 3073 O
the 253 256 3074 3077 O
absence 257 264 3078 3085 O
of 265 267 3086 3088 O
an 268 270 3089 3091 O
external 271 279 3092 3100 O
trigger 280 287 3101 3108 O

Subjects 0 8 3109 3117 O
with 9 13 3118 3122 O
a 14 15 3123 3124 O
history 16 23 3125 3132 O
of 24 26 3133 3135 O
symptomatic 27 38 3136 3147 O
interstitial 39 51 3148 3160 B-chronic_disease
lung 52 56 3161 3165 I-chronic_disease
disease 57 64 3166 3173 I-chronic_disease

Subjects 0 8 3174 3182 O
with 9 13 3183 3187 O
active 14 20 3188 3194 O
concurrent 21 31 3195 3205 O
malignancies 32 44 3206 3218 B-cancer
are 45 48 3219 3222 O
excluded 49 57 3223 3231 O
i.e. 58 62 3232 3236 O
cancers 63 70 3237 3244 B-cancer
other 71 76 3245 3250 O
than 77 81 3251 3255 O
NSCLC 82 87 3256 3261 B-cancer

Subjects 0 8 3262 3270 O
with 9 13 3271 3275 O
brain 14 19 3276 3281 B-cancer
metastasis 20 30 3282 3292 I-cancer
are 31 34 3293 3296 O
excluded 35 43 3297 3305 O
from 44 48 3306 3310 O
this 49 53 3311 3315 O
study 54 59 3316 3321 O
, 59 60 3321 3322 O
and 61 64 3323 3326 O
all 65 68 3327 3330 O
patients 69 77 3331 3339 O
should 78 84 3340 3346 O
have 85 89 3347 3351 O
brain 90 95 3352 3357 O
imaging 96 103 3358 3365 O
( 104 105 3366 3367 O
either 105 111 3367 3373 O
MRI 112 115 3374 3377 O
brain 116 121 3378 3383 O
or 122 124 3384 3386 O
CT 125 127 3387 3389 O
brain 128 133 3390 3395 O
with 134 138 3396 3400 O
contrast 139 147 3401 3409 O
) 147 148 3409 3410 O
prior 149 154 3411 3416 O
to 155 157 3417 3419 O
enrollment 158 168 3420 3430 O

The 0 3 3431 3434 O
effects 4 11 3435 3442 O
of 12 14 3443 3445 O
nivolumab 15 24 3446 3455 B-treatment
on 25 27 3456 3458 O
the 28 31 3459 3462 O
developing 32 42 3463 3473 O
human 43 48 3474 3479 O
fetus 49 54 3480 3485 O
are 55 58 3486 3489 O
unknown 59 66 3490 3497 O

This 0 4 3498 3502 O
may 5 8 3503 3506 O
include 9 16 3507 3514 O
clinical 17 25 3515 3523 O
stage 26 31 3524 3529 B-clinical_variable
IB 32 34 3530 3532 I-clinical_variable
( 35 36 3533 3534 O
≥4 36 38 3534 3536 O
cm 38 40 3536 3538 I-lower_bound
) 40 41 3538 3539 O
, 41 42 3539 3540 O
II 43 45 3541 3543 O
and 46 49 3544 3547 O
IIIA(see 50 58 3548 3556 O
Appendix 59 67 3557 3565 O
A 68 69 3566 3567 O
) 69 70 3567 3568 O

Total 0 5 3569 3574 O
Bilirubin 6 15 3575 3584 B-clinical_variable
≤ 16 17 3585 3586 O
1.5 18 21 3587 3590 B-upper_bound
x 22 23 3591 3592 I-upper_bound
ULN 24 27 3593 3596 I-upper_bound
( 28 29 3597 3598 O
except 29 35 3598 3604 O
subjects 36 44 3605 3613 O
with 45 49 3614 3618 O
Gilbert 50 57 3619 3626 B-chronic_disease
Syndrome 58 66 3627 3635 I-chronic_disease
, 66 67 3635 3636 O
who 68 71 3637 3640 O
can 72 75 3641 3644 O
have 76 80 3645 3649 O
total 81 86 3650 3655 O
bilirubin 87 96 3656 3665 B-clinical_variable
< 97 98 3666 3667 O
3.0 99 102 3668 3671 B-upper_bound
mg 103 105 3672 3674 I-upper_bound
/ 105 106 3674 3675 I-upper_bound
dL 106 108 3675 3677 I-upper_bound
) 108 109 3677 3678 O

Underlying 0 10 3679 3689 O
medical 11 18 3690 3697 O
conditions 19 29 3698 3708 O
that 30 34 3709 3713 O
, 34 35 3713 3714 O
in 36 38 3715 3717 O
the 39 42 3718 3721 O
Investigator 43 55 3722 3734 O
's 55 57 3734 3736 O
opinion 58 65 3737 3744 O
, 65 66 3744 3745 O
will 67 71 3746 3750 O
make 72 76 3751 3755 O
the 77 80 3756 3759 O
administration 81 95 3760 3774 O
of 96 98 3775 3777 O
study 99 104 3778 3783 B-treatment
drug 105 109 3784 3788 I-treatment
hazardous 110 119 3789 3798 O
or 120 122 3799 3801 O
obscure 123 130 3802 3809 O
the 131 134 3810 3813 O
interpretation 135 149 3814 3828 O
of 150 152 3829 3831 O
toxicity 153 161 3832 3840 O
or 162 164 3841 3843 O
adverse 165 172 3844 3851 O
events 173 179 3852 3858 O

WOCBP 0 5 3859 3864 O
must 6 10 3865 3869 O
have 11 15 3870 3874 O
a 16 17 3875 3876 O
negative 18 26 3877 3885 B-pregnancy
serum 27 32 3886 3891 I-pregnancy
or 33 35 3892 3894 I-pregnancy
urine 36 41 3895 3900 I-pregnancy
pregnancy 42 51 3901 3910 I-pregnancy
test 52 56 3911 3915 O
( 57 58 3916 3917 O
minimum 58 65 3917 3924 O
sensitivity 66 77 3925 3936 B-clinical_variable
25 78 80 3937 3939 B-lower_bound
IU 81 83 3940 3942 I-lower_bound
/ 83 84 3942 3943 I-lower_bound
L 84 85 3943 3944 I-lower_bound
or 86 88 3945 3947 O
equivalent 89 99 3948 3958 O
units 100 105 3959 3964 O
of 106 108 3965 3967 O
HCG 109 112 3968 3971 O
) 112 113 3971 3972 O
within 114 120 3973 3979 O
two 121 124 3980 3983 B-upper_bound
weeks 125 130 3984 3989 I-upper_bound
of 131 133 3990 3992 O
registration 134 146 3993 4005 O

Women 0 5 4006 4011 B-gender
must 6 10 4012 4016 O
not 11 14 4017 4020 O
be 15 17 4021 4023 O
breastfeeding 18 31 4024 4037 O

Women 0 5 4038 4043 B-gender
who 6 9 4044 4047 O
are 10 13 4048 4051 B-pregnancy
pregnant 14 22 4052 4060 I-pregnancy
or 23 25 4061 4063 O
nursing 26 33 4064 4071 O

non 0 3 4072 4075 B-cancer
melanoma 4 12 4076 4084 I-cancer
skin 13 17 4085 4089 I-cancer
cancers 18 25 4090 4097 I-cancer
, 25 26 4097 4098 O
in 27 29 4099 4101 B-cancer
situ 30 34 4102 4106 I-cancer
bladder 35 42 4107 4114 I-cancer
, 42 43 4114 4115 O
gastric 44 51 4116 4123 B-cancer
, 51 52 4123 4124 O
breast 53 59 4125 4131 B-cancer
, 59 60 4131 4132 O
colon 61 66 4133 4138 B-cancer
or 67 69 4139 4141 O
cervical 70 78 4142 4150 B-cancer
cancers 79 86 4151 4158 I-cancer
/ 86 87 4158 4159 I-cancer
dysplasia 87 96 4159 4168 I-cancer

other 0 5 4169 4174 O
immunosuppressive 6 23 4175 4192 B-treatment
medications 24 35 4193 4204 I-treatment
within 36 42 4205 4211 O
14 43 45 4212 4214 B-upper_bound
days 46 50 4215 4219 I-upper_bound
of 51 53 4220 4222 O
study 54 59 4223 4228 O
drug 60 64 4229 4233 O
administration 65 79 4234 4248 O

